No profile data available.
Pasithea Therapeutics Corp. (KTTA) is a healthcare company in the additional cancer treatment drugs industry, based in Miami Beach, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$20.43 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $15.62 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers.
Pasithea Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$15.62 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Curis, Inc. (CRIS), Abpro Holdings, Inc. (ABP), Allarity Therapeutics, Inc. (ALLR), TScan Therapeutics, Inc. (TCRX).